BOSTON & PERTH, Australia--(BUSINESS WIRE)--Global drug delivery company pSivida Limited (ASX:PSD) (NASDAQ:PSDV) (Xetra:PSI) announced today that it is has entered into an exclusive negotiation period with a major global pharmaceutical company, to acquire a worldwide, royalty bearing license to make, use and sell products using pSivida’s drug delivery technologies.
